Cruickshank J K, Anderson N M, Wadsworth J, Young S M, Jepson E
Central Middlesex Hospital, Park Royal, London.
BMJ. 1988 Nov 5;297(6657):1155-9. doi: 10.1136/bmj.297.6657.1155.
To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure.
Double blind, placebo controlled, random order crossover trial with four week placebo run in period and two six week active phases separated by a two week placebo washout period.
Outpatient department of a general hospital in a multiethnic health department. Patients--Diabetic patients with hypertension. Four dropped out before randomisation; 25 black and 14 white patients completed the trial.
Patients given slow release verapamil 120 mg or 240 mg twice daily with placebo or metoprolol 50 mg or 100 mg twice daily with placebo. Treatment for diabetes (diet alone or with oral hypoglycaemic drugs) remained unchanged.
Comparison of changes in blood pressure in the two groups taking both drugs.
Metoprolol had little effect on blood pressure in black patients (mean fall 4.0 mm Hg systolic (95% confidence interval -2.5 to 10.4 mm Hg), 4.3 mm Hg diastolic (-0.8 to 9.5)) but more effect in white patients (mean falls 13.4 mm Hg (0.1 to 26.7) and 10.6 mm Hg (4.5 to 16.7) respectively). Verapamil was more effective in both groups, with mean falls of 8.8 mm Hg (2.4 to 15.0) and 8.1 mm Hg (5.0 to 11.2) in black patients and 19.1 mm Hg (5.4 to 32.9) and 11.4 mm Hg (0.9 to 22.0) in white patients. Heart fate fell significantly in black patients taking metoprolol, which suggested compliance with treatment. Metabolic variables were unaltered by either treatment. Plasma renin activity was low in both groups after metoprolol treatment, but change in blood pressure could not be predicted from baseline plasma renin activity. Urinary albumin:creatinine ratio was independently related to baseline blood pressure but not significantly changed by treatment.
beta Blockers alone are not effective in treating hypertension in black diabetics. Verapamil is effective but less so than in white patients. As yet no ideal monotherapy exists for hypertension in black patients.
比较高血压黑人糖尿病患者与白人糖尿病患者对钙拮抗剂维拉帕米和β受体阻滞剂美托洛尔的血压反应,并监测与血压下降相关的尿白蛋白排泄情况。
双盲、安慰剂对照、随机顺序交叉试验,有为期4周的安慰剂导入期,两个为期6周的活性药物治疗期,中间间隔2周的安慰剂洗脱期。
一家多民族健康部门综合医院的门诊部。患者——高血压糖尿病患者。4例在随机分组前退出;25例黑人患者和14例白人患者完成试验。
患者分别给予缓释维拉帕米120mg或240mg,每日2次,加用安慰剂,或美托洛尔50mg或100mg,每日2次,加用安慰剂。糖尿病治疗(单纯饮食或联合口服降糖药)保持不变。
比较两组服用两种药物时血压的变化。
美托洛尔对黑人患者血压影响很小(收缩压平均下降4.0mmHg(95%置信区间-2.5至10.4mmHg),舒张压下降4.3mmHg(-0.8至9.5)),但对白人患者影响更大(收缩压平均下降分别为13.4mmHg(0.1至26.7),舒张压下降10.6mmHg(4.5至16.7))。维拉帕米在两组中均更有效,黑人患者收缩压平均下降8.8mmHg(2.4至15.0),舒张压下降8.1mmHg(5.0至11.2);白人患者收缩压平均下降19.1mmHg(5.4至32.9),舒张压下降11.4mmHg(0.9至22.0)。服用美托洛尔的黑人患者心率显著下降,提示治疗依从性良好。两种治疗均未改变代谢指标。美托洛尔治疗后两组血浆肾素活性均较低,但血压变化无法根据基线血浆肾素活性预测。尿白蛋白/肌酐比值与基线血压独立相关,但治疗后无显著变化。
单独使用β受体阻滞剂对黑人糖尿病患者的高血压治疗无效。维拉帕米有效,但效果不如白人患者。目前尚无理想的单一药物治疗黑人患者的高血压。